医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ImpediMed’s SOZO® Digital Health Platform Voted Among Top Five Finalists for Southern California ABBY Awards

2018年11月27日 PM11:00
このエントリーをはてなブックマークに追加


 

BRISBANE, Australia & CARLSBAD, Calif.

ImpediMed Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), announces that its SOZO® Digital Health Platform has been voted among the top five finalists for ABL Organization’s 19th Innovations in Healthcare ABBY Awards in the category of Innovative Health IT or Digital Health Technology. Richard Carreon, managing director and CEO, ImpediMed, will present key information about SOZO, a leading, non-invasive and FDA-cleared BIS digital health platform that measures, monitors and manages fluid accumulation in patients with certain conditions resulting from cancer treatment, such as lymphedema (LE) and heart failure (HF).

“This recognition further elevates the importance of SOZO to enhance cancer survivorship,” says Carreon. “It is breakthrough technology that provides physicians with easy access to an unprecedented level of information and data without the need for an invasive procedure. With increased adoption in healthcare systems nationwide, and with new research validating its effectiveness, an even greater number of cancer survivors can benefit with better health outcomes and improved quality of life.”

Carreon points to the recently published MD Anderson study to assess the validity of L-Dex BIS measurements for evaluating the effectiveness of interventions to treat lymphedema. Using ImpediMed technology, researchers conclude that the L-Dex correlates most closely with all measures and is the recommended metric when using BIS. Findings support the adjunctive use of the L-Dex ratio with limb volume measurements for objective diagnosis, evaluation of lymphedema severity, longitudinal serial evaluation of lymphedema, and response to conservative and surgical interventions.

About ImpediMed

Founded and headquartered in Brisbane, Australia, with U.S. and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status. ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications, including heart failure and lymphedema, sold in select markets globally. Visit www.impedimed.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181127005103/en/

CONTACT

Media:
Laura Carabello
lcarabello@cpronline.com
201.641.1911
x12

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • CHA Health Systems Subsidiary to Form the Largest Healthcare Network to Provide Premium Comprehensive Suite of Medical Services
  • BIO Announces Partnership with Taiwan BIO for 2019 Conference and Exhibition
  • 沙特卫生部与Masimo宣布,采用Masimo技术来实现全国新生儿CCHD筛查流程的自动化
  • Dr. Reddy’s Laboratories Announces the Re-Launch of Its Buprenorphine and Naloxone Sublingual Film after Favorable Ruling in Patent Litigation
  • KCI Launches ABTHERA™ Therapy in Japan